At this year's World Congress of Nephrology, positive results were presented from Novartis's pre-specified interim analysis of the Phase III APPLAUSE-IgAN clinical trial. According to the analysis, the use of Fabhalta (iptacopan) was shown to reduce proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN) compared to placebo. The drug potentially fills an unmet need in the IgAN space as it has an alternate mechanism of action to currently marketed therapies, says GlobalData, a leading data and analytics company.
APPLAUSE-IgAN is an ongoing, randomized, double-blind, placebo-controlled, multicenter, Phase III study to assess the safety and efficacy of Fabhalta. The interim analysis results showed that Fabhalta achieved a 38.3% reduction in proteinuria as measured by 24-hour urine protein to creatinine ratio at nine months versus placebo. Additionally, Fabhalta's safety profile was consistent with previously reported data.
Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: "According to key opinion leaders (KOLs) interviewed by GlobalData, unmet needs in the kidney disease space include next-generation therapies with alternate mechanisms of action and enhanced clinical profiles. This study could be of high clinical value to nephrologists who are seeking an optimal treatment of choice for IgAN patients."
If approved, Fabhalta will become the first treatment for IgAN that specifically targets the alternative complement pathway. Iptacopan acts as an inhibitor of complement factor B and was approved in December 2023 for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Jaddoo concludes: "Novartis completed the acquisition of Chinook Therapeutics in August 2023. The deal was valued at up to $3.5 billion and strengthened Novartis's kidney disease portfolio with Chinook's lead drugs astrasentan and zigakibart for IgAN. This acquisition was significant as it will help Novartis to better address the therapeutic needs of IgAN patients."
Media Enquiries
If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.
GlobalData plc published this content on
25 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
25 April 2024 13:54:06 UTC.
GlobalData Plc is a United Kingdom-based intelligence provider. The Company's principal activity is to provide business information in the form of proprietary data, analytics, and insights to clients in multiple sectors. The Company maintains a centralized operating model and single product platform (One Platform), which is underpinned by a common taxonomy, shared development resource, and new data science technologies. The Company offers Intelligence Centers, which includes market intelligence and thematic intelligence; Consultancy, which provides custom solutions, and Marketplace, which includes report store, company profiles, direct data services, newsletters and free intelligence. It serves corporates, financial institutions, professional services and others. It covers various industries, including aerospace, defense and security, agribusiness, apparel, automotive, banking and payments, construction, consumer, foodservice, healthcare, insurance, medical devices, and mining.